Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 343

1.

Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines.

Shoji T, Nishizawa Y.

Ther Apher Dial. 2006 Aug;10(4):305-15. Review.

PMID:
16911182
2.

The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.

Pennell P, Leclercq B, Delahunty MI, Walters BA.

Clin Nephrol. 2006 Nov;66(5):336-47.

PMID:
17140163
3.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

4.

Is lipid control necessary in hemodialysis patients?

Cheung AK.

Clin J Am Soc Nephrol. 2009 Dec;4 Suppl 1:S95-101. doi: 10.2215/CJN.04780709. Review.

5.

Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.

Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.

Clin Ther. 2007 Aug;29(8):1671-81.

PMID:
17919548
6.

Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.

Marrs JC, Saseen JJ.

Pharmacotherapy. 2010 Aug;30(8):823-9. doi: 10.1592/phco.30.8.823. Review.

PMID:
20653359
7.

[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].

Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.

Nefrologia. 2008;28 Suppl 3:39-48. Spanish.

8.

Managing dyslipidemia in chronic kidney disease.

Harper CR, Jacobson TA.

J Am Coll Cardiol. 2008 Jun 24;51(25):2375-84. doi: 10.1016/j.jacc.2008.03.025. Review.

9.

[Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].

Ravera M, Paoletti E.

Ital Heart J Suppl. 2004 Jun;5(6):436-44. Review. Italian.

PMID:
15471148
10.

Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients.

Desmeules S, Arcand-Bossé JF, Bergeron J, Douville P, Agharazii M.

Am J Kidney Dis. 2005 Jun;45(6):1067-72.

PMID:
15957136
11.
12.

Atherogenic lipoproteins in end-stage renal disease.

Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S30-3. Review.

PMID:
11576918
13.

Pathogenesis and management of the dyslipidemia of the metabolic syndrome.

Raal FJ.

Metab Syndr Relat Disord. 2009 Apr;7(2):83-8. doi: 10.1089/met.2008.0079. Review.

PMID:
19400742
14.

Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.

Tsimihodimos V, Dounousi E, Siamopoulos KC.

Am J Nephrol. 2008;28(6):958-73. doi: 10.1159/000144024. Epub 2008 Jul 9. Review.

15.

[Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].

Kes P, Reiner Z, Brunetta B.

Lijec Vjesn. 2002 Nov-Dec;124(11-12):372-7. Review. Croatian.

PMID:
12679979
16.

Management of dyslipidemias in patients with diabetes and chronic kidney disease.

Molitch ME.

Clin J Am Soc Nephrol. 2006 Sep;1(5):1090-9. Epub 2006 Jul 26. Review.

17.

Impact of dyslipidemia in end-stage renal disease.

Prichard SS.

J Am Soc Nephrol. 2003 Sep;14(9 Suppl 4):S315-20. Review.

18.

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.

Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R Jr, Levin A, Masri B, Parekh R, Wanner C, Wheeler DC, Wilson PW; National Kidney Foundation.

Am J Transplant. 2004;4 Suppl 7:13-53.

19.

Dyslipidaemia in chronic kidney disease.

Krane V, Wanner C.

Minerva Urol Nefrol. 2007 Sep;59(3):299-316. Review.

PMID:
17912226
20.

K/DOQI gets to the heart of managing dyslipidemias in patients with CKD.

Benner D.

Nephrol Nurs J. 2005 May-Jun;32(3):337-8.

PMID:
16035475
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk